Introduction {#cesec10}
============

Despite the gains made towards elimination of *Plasmodium falciparum* malaria in the past 15 years, many countries still have endemic transmission[@bib1] and are increasingly looking to new strategies to accelerate progress. Mass drug administration (MDA) involves the time-limited distribution of drugs to a target population, irrespective of infection status. It has been used only sporadically against malaria in most settings, and cluster-randomised trials, the most robust studies of the effect of MDA on transmission, are few.[@bib2], [@bib3] However, MDA has received renewed interest as a strategy to clear chronic asymptomatic infections ([NCT01872702](ctgov:NCT01872702){#interrefs10}) and rapidly reduce transmission.[@bib4], [@bib5]

In September, 2015, WHO\'s Malaria Policy Advisory Committee recommended for the first time the use of MDA in specific circumstances: when transmission is close to being interrupted, vector control, effective surveillance, and access to case management are at high coverage, and importation of infection is minimal; as a component of accelerated elimination in areas of the Greater Mekong Subregion, which are under threat of multidrug resistance; or for malaria epidemics or during complex emergencies.[@bib6] National malaria control programmes and partners need to decide what role, if any, MDA should have in control and elimination strategies. To answer this question, the best operational strategies for MDA and how best to combine MDA with other interventions need to be established.

To help with the Malaria Policy Advisory Committee\'s decision making, an evidence review group was established to synthesise available evidence for the effect of MDA on transmission of malaria.[@bib7] This synthesis included a few prospective field trials, retrospective analyses of previous MDAs, and a mathematical-model comparison analysis. Mathematical models are a useful way of assessing the knowledge accumulated from field trials of MDA and predicting how effectiveness might vary in settings where MDA has not yet been tested. The Malaria Modelling Consortium was tasked to compare findings from four established models (OpenMalaria,[@bib8] EMOD Disease Transmission Kernel \[DTK\],[@bib9] Imperial,[@bib10], [@bib11] and Mahidol Oxford Tropical Medicine Research Unit (MORU\][@bib12], [@bib13]) on the effectiveness of MDA in different settings. Model development involves deciding on model structure, parameters, and assumptions, validation against epidemiological data, and assessment of uncertainties at each stage of this process.

Research in context**Evidence before this study**We did not do a search of published work, because three comprehensive reviews have been published in the past 4 years. A Cochrane review done in 2013 found two cluster-randomised trials, eight non-randomised controlled studies, and 22 uncontrolled before--after studies of mass drug administration. Most studies showed a substantial initial effect on parasitaemia. However, there was little evidence for effects beyond 6 months. Two further comprehensive reviews published in 2015 had wider inclusion criteria, and included published and unpublished work and studies not yet published. These reviews showed that mass drug administration was implicated in local elimination of malaria in some settings, particularly remote areas with small populations and low initial malaria transmission, but not in areas of higher transmission. Mass drug administration has been simulated in several mathematical modelling studies but, as in field studies, many factors---such as the number of doses given, number of rounds of treatment, choice of drugs, local malaria transmission intensity, and outcomes of interest---have varied greatly, all of which are likely to affect outcomes.**Added value of this study**In this study, a consortium of modelling groups investigated the degree of consensus of four established malaria transmission models in terms of the main determinants of the effect of mass drug administration and how large an effect on prevalence is likely to be achieved. In consultation with partners who are doing field trials of mass drug administration, we chose various programme options (eg, number of rounds, choice of drug) that were considered logistically feasible. We standardised many inputs and outputs of the models, such as initial slide prevalence, outcomes of interest, and implementation options. Our analysis showed---despite many differences in assumptions between the four models, for example about the underlying transmission dynamics of malaria---broad consensus between the models on how mass drug administration should be implemented to optimise effects, and the settings in which such programmes will be most effective.**Implications of all the available evidence**High coverage in the target population and mass drug administration in more than 1 year are important to maximise reductions in transmission. Reductions in transmission last longest in low-transmission settings but, unless elimination and prevention of reintroduction are achieved, malaria transmission will return to pre-intervention levels after the programme of mass drug administration finishes.

We report the results of the Malaria Modelling Consortium\'s MDA model comparison and their implications for the utility of MDA. Our aim for this analysis is to help with decisions on the relative prioritisation of MDA within wider malaria-control strategies.

Methods {#cesec20}
=======

Malaria-control programmes implementing MDA need to decide on several operational factors, including the number of rounds, timing, and frequency of treatment. Furthermore, the effect of MDA can be influenced by epidemiological factors in each setting, such as malaria transmission level and infection importation rates. The Malaria Modelling Consortium collaborated with partners doing field trials of MDA to identify probable scenarios for MDA deployment and common operational choices that would need to be made within realistic logistic constraints.

First, a standard MDA intervention scenario was defined to use as a basis for comparison ([table 1](#tbl1){ref-type="table"}). This scenario consisted of two rounds of treatment per year, 5 weeks apart, with a standard regimen of dihydroartemisinin--piperaquine at 70% effective coverage, for 2 years. A standard setting was chosen ([table 1](#tbl1){ref-type="table"}), specifying 5% slide *P falciparum* parasite rate in 2--10-year-olds (*Pf*PR~2--10~) before MDA, intermediate seasonal variation in transmission with one rainy season, and no importation of infection. In further simulations, we varied operational factors that are of primary interest because they can be adjusted in an MDA programme: the number of rounds per year, the effective coverage of each round, the interval between rounds, and the duration of the MDA programme. Each model was used to do a multivariate analysis that simulated the baseline conditions with every combination of the selected parameters ([table 1](#tbl1){ref-type="table"}), producing 48 different MDA programmes. We also tested how the effect of MDA could vary depending on the local setting with respect to seasonal timing, vector control, importation of infection, and drug resistance; these analyses were done in selected models according to which were most appropriate for each setting.Table 1Model input parameters for programme options and local settings for mass drug administration**Standard scenario valueValues when variedProgrammatic considerations**Rounds of mass drug administration per year23Effective coverage[\*](#tbl1fn1){ref-type="table-fn"} (%)70%30%, 50%, 90%Coverage correlation between rounds1[†](#tbl1fn2){ref-type="table-fn"} or 0[‡](#tbl1fn3){ref-type="table-fn"}0 or 1Interval between rounds5 weeks4 weeks, 6 weeksDuration of programme2 years1 yearTime of year when mass drug administration beginsOptimum (as defined by each group) in a Zambia-like seasonalityEach month of the yearOther interventionsInsecticide-treated bednets at 80% effective coverage and access to passive treatment with artemisinin-based combination therapy at 60% throughout the simulationRemoval of vector control, simulated by a ten-fold increase in the emergence rate of adult mosquitos starting at the beginning of the year in which mass drug administrated is implementedChoice of drugLong-lasting artemisinin-based combination therapy with properties similar to dihydroartemisinin--piperaquine..**Transmission setting characteristics**Baseline transmission intensity5% *Pf*PR~2--10~, as measured by microscopy1 to 10Importation of malaria casesNone0·4--1·6 infections per 10 000 people per year[@bib14]Population size10 0001000Artemisinin resistance0%VariableSeasonality profileZambia-based single annual rainy season profileTwo rainy seasons per year, no seasonal variation in transmission[^2][^3][^4][^5]

The outcome metric was the percentage reduction in annual mean all-age prevalence of *P falciparum* as measured by PCR (*Pf*PR~PCR~) in the third year after the final round of MDA. The models assessed represent four different ways of simulating malaria transmission and MDA, and a summary of their characteristics and functionality is given in [table 2](#tbl2){ref-type="table"}.[@bib11], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29]Table 2Summary of models of malaria transmission**EMOD DTKImperialMORUOpenMalaria**Institutional homeInstitute for Disease ModellingImperial College LondonMahidol Oxford Tropical Medicine Research UnitSwiss Tropical and Public Health InstituteType of model and referencesIndividual-based stochastic microsimulation[@bib16], [@bib17]Individual-based stochastic microsimulations of malaria in human beings linked to a stochastic compartmental model for mosquitoes[@bib11]Deterministic compartmental model described by differential equations,[@bib18] including drug action on each stage of the infectionSingle-location individual-based simulation of malaria in human beings[@bib14] linked to deterministic model of malaria in mosquitoes[@bib19]How infections are trackedTracks parasite densities of different surface-antigen typesTracks membership of categories of infection (symptomatic, asymptomatic, submicroscopic, treated)Tracks membership of categories of infectionTracks parasite densities corresponding to different infection eventsRelationship between entomological innoculation rate and prevalenceImmunity is acquired through cumulative exposure to different antigenic determinants,[@bib20] with heterogeneity in individual biting rates includedImmunity is acquired through cumulative exposure to mosquito bites, with heterogeneity in individual biting rates includedSubdivides population into non-immune and immune classesSubmodels of infection of human beings[@bib14] and of blood-stage parasite densities, with main immune effects controlling parasite densities[@bib21]Duration of infectionsInfection duration based on malaria therapy[@bib20] and cross-sectional survey data[@bib22]Infection duration based on fitting to asexual parasite prevalence data by age, transmission intensity, seasonalityInfection duration based on malaria therapy data and data from endemic areasInfection duration based on malaria therapy data[@bib21]Effect of mass drug administration or case managementReduces blood-stage parasite densities according to age-specific and dose-specific pharmacokinetics and pharmacodynamics,[@bib22] with corresponding clearance and prophylactic effectsTruncates infections and has subsequent prophylactic effect based on fitting pharmacokinetic and pharmacodynamic models to field studiesPost-treatment prophylactic period derived from field studies of time to next infectionTruncates infections, and has subsequent prophylactic effect based on pharmacokinetic and pharmacodynamic studiesValidation against trials of mass drug administration or mass screening and treatmentAssessed against MACEPA trial of mass screening and treatment in southern Zambia[@bib23]Assessed against a controlled trial[@bib24] of mass drug administration in Burkina Faso (model slightly optimistic about effect *vs* data), and the MACEPA trial of mass screening and treatment in southern Zambia (model matched data)Fitted to a trial of mass drug administration in Cambodia[@bib25]Fitted to the data of the Garki project (Matsari),[@bib26] and assessed against the MACEPA trial of mass screening and treatment in southern Zambia[@bib27]Infectiousness to mosquitoesA function of mature gametocyte and cytokine densities[@bib20], [@bib22]Related to asexual parasite dynamics and lagged to allow for development of gametocytesInfected individuals have a constant infectiousnessLagged function of asexual parasite density[@bib28]Heterogeneity in exposureAge-dependent biting[@bib29] and configurable distribution of household variability (the latter disabled in this analysis)IncludedNot includedIncludedInitial state..Back-calculating required mosquito density to achieve given initial prevalence at an approximate steady state in the presence of treatment and long-lasting insecticide-treated netsSet transmission rate to achieve given initial prevalence at an approximate steady state in the presence of treatmentBack-calculating required mosquito density to achieve given initial prevalence at an approximate steady state in the presence of treatmentSource of seasonality patternRainfall and imputed temperature[@bib29] driving larval habitat model fitted to clinical incidence patterns in Sinazongwe and Gwembe districts, ZambiaRainfall data from Zambia combined with larval and adult mosquito modelSame entomological innoculation rate input as Imperial modelBased on pattern for southern Zambia[@bib29]Age-structured modelYesYesNoYesSimulation of correlated rounds of interventionYesYesNoYes[^6]

Role of the funding source {#cesec30}
--------------------------

EMS and EAO are or have been employed by the study funder, and were involved in data collection, analysis, and interpretation, and writing of the Article. However, they were not involved in study design The funder had no further role in study design; data collection, analysis, or interpretation; or writing of the Article. The corresponding author had access to all study data and was responsible for the final decision to submit for publication.

Results {#cesec40}
=======

In all four models, simulated prevalence fell substantially immediately after MDA ([figure 1](#fig1){ref-type="fig"}) as a result of successful clearance of infection and the prophylactic effect of piperaquine, a long-acting artemisinin-combination therapy partner drug. However, in the absence of elimination, the models predicted that prevalence of infection would thereafter return to pre-intervention levels (at different rates in different models). After the prophylactic effect of the partner drug has declined, the key factors that determine local transmission intensity, such as the density of mosquitoes, have not been permanently changed. Thus, without some other long-term intervention, such as improved vector control, the effects of MDA were predicted to be transient.Figure 1Sample simulated output from four different models of effect of mass drug administration on all-age PCR prevalence of *Plasmodium falciparum* infectionFrom year −1 to year 0, the models are at equilibrium. The timing of each round of mass drug administration in each model is shown by coloured arrows. The four different models show the output under the standard intervention scenario (70% coverage, 2 years of mass drug administration, two rounds per year, 5 weeks between rounds, seasonal transmission \[based on Zambia\], and 5% mean annual prevalence pre-intervention by microscopy in 2--10-year-olds). DTK=Disease Transmission Kernel. MORU=Mahidol Oxford Tropical Medicine Research Unit.

Although the four different models showed similar trends in the effects of MDA with time, substantial differences were noted in both simulated pre-intervention transmission and the magnitude of the effect ([Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}). Pre-intervention *Pf*PR~PCR~ differed between models because we standardised these initial conditions to 5% slide prevalence in 2--10-year-olds, and the models make several different assumptions, for example about the relation between slide and PCR prevalence. The EMOD DTK and MORU models predicted a reduction in *Pf*PR~PCR~ of 64% in the third year after MDA, OpenMalaria a reduction of 58%, and Imperial a reduction of 19%. These differences were caused by many different assumptions, including the relation between entomological inoculation rate, prevalence, and the basic case reproduction number (R~0~); the effect of case management; the degree of stochastic variability; and the dynamics of immunity.Figure 2Percentage reduction in mean annual all-age PCR prevalence of *Plasmodium falciparum* in the third year after mass drug administrationNumbers in boxes are percentage reductions. The darker the colour, the larger the reduction. DTK=Disease Transmission Kernel. MORU=Mahidol Oxford Tropical Medicine Research Unit.

Despite the differences in effect size predicted by the different models, there was generally greater agreement as to the relative effect of different operational choices. Effective coverage had a large effect on percentage reduction in *Pf*PR~PCR~ in all models. For example, the median percentage reduction in *Pf*PR~PCR~ in the standard scenario at 30% coverage was 15% (range across models 10--30); at 70% coverage, it was 61% (range 19--64; [figure 2](#fig2){ref-type="fig"}). Duration of intervention was also important in all models, with prevalence estimated to remain low for longer with 2 years of MDA than with 1 year of MDA ([figure 2](#fig2){ref-type="fig"}). When multiple rounds of MDA are done, all models showed that coverage overlap substantially affects MDA. For example, if participation was entirely random in each round, two rounds of MDA at 70% coverage would reach roughly 90% of the population with one or more treatment courses. However, if the same individuals participated in each round, then two rounds at 70% coverage would reach only 70% of the population. In reality, the situation is likely to be somewhere between the two extremes, and strategies that specifically target individuals missed in the first round are likely to be more effective as long as these strategies do not come at the expense of maximising the total number of individuals treated per year.

All four models suggested that, with closely spaced rounds of MDA (ie, intervals of 4--6 weeks), the most important operational factor determining effect is the proportion of the population who do not receive any treatment in any round ([figure 3](#fig3){ref-type="fig"}). Implementation of three rather than two rounds of treatment per year had negligible effects if the same individuals participated in each round at intervals of 4--6 weeks, but resulted in better outcomes if additional people were reached in the third round who had not previously received treatment that year. Spacing within-year MDA rounds 4 weeks apart rather than 6 weeks apart made little difference in terms of overall effects.Figure 3Overlap in coverage between rounds of mass drug administration and effect on *Pf*PR~PCR~(A) shows the proportion of the population receiving one or more treatment courses after two rounds of mass drug administration, each at 70% coverage, with either random participation or the same individuals participating each time. (B) shows the percentage reduction in *Pf*PR~PCR~ 3 years after mass drug administration according to the proportion of the population not receiving treatment in any rounds in the baseline scenario. Blue triangles represent two rounds of mass drug administration randomly targeted at 30%, 50%, 70%, and 90% coverage; red dots represent the same two rounds of mass drug administration in which the same individuals are treated in each round. Results shown are from the OpenMalaria model. *Pf*PR~PCR~=*Plasmodium falciparum* parasite rate as measured by PCR.

In settings with one rainy season a year, all models predicted greater reductions in *Pf*PR~PCR~ if MDA was done during the dry season or at the end of the rainy season, as previously found in similar analyses by the separate models.[@bib12], [@bib13], [@bib30], [@bib31], [@bib32] In the Imperial model, reductions in *Pf*PR~PCR~ were as much as 1·45 times greater if MDA was done in the dry season or at the end of the rainy season than at the beginning of the rainy season. Seasonal timing has less of an effect on *Pf*PR~PCR~ in the OpenMalaria and MORU models. In a setting with two rainy seasons per year, we predicted that timing of MDA had less of an effect, because transmission was more evenly spread throughout the year. At a given mean baseline slide prevalence, MDA was predicted to be marginally more effective in a seasonal setting (at the optimum time) than in a non-seasonal setting.

The introduction of MDA while vector control was simultaneously removed led to a sudden and large increase in simulated all-age prevalence, and the subsequent MDA programme did very little to reduce this shift even in the short term (OpenMalaria and Imperial models). We predicted, therefore, that an MDA programme of this type is insufficient to replace vector control, even at the highest levels of coverage.[@bib33]

In a high prevalence setting (ie, 10% *Pf*PR~2--10~), the percentage reduction in *Pf*PR~PCR~ was considerably lower in all the models compared with that in a setting with 5% prevalence. We predicted that, even with high coverage (90%), three rounds per year, and 2 years of intervention, *Pf*PR~PCR~ 3 years later would be reduced by only a median of 48% (range across models 19--95) from its pre-intervention level, compared with 80% (range across models 56--100) in the setting with 5% baseline prevalence. This disparity is because transmission rebounds more rapidly in a higher transmission area. However, the absolute reduction in transmission is greater in higher prevalence settings because more infections are cleared.

When PfPR~2--10~ is 5%, cases imported at a low rate (as in the WHO-recommended MDA use scenarios), based on data from Zanzibar,[@bib34] represent a very small proportion of the total infections in the population, and therefore make little difference to MDA effectiveness. However, when PfPR~2--10~ is lower, imported cases would be instrumental to increasing transmission. MDA more easily caused stochastic extinction in smaller than in bigger simulated populations in all the models. Finally, some evidence (only tested with the MORU model) suggested that MDA with artemisinin-combination therapies could speed up the selection of artemisinin-resistant parasite strains ([figure 4](#fig4){ref-type="fig"}). However, the size of this effect could be limited by the high selection pressure already imposed from management of symptomatic cases.Figure 4Effect of MDA with artemisinin-combination therapy on malaria prevalence and the percentage of parasites that are artemisinin resistantResults shown are from the MORU model. Blue lines show parasite prevalence, whereas red lines show the percentage artemisinin resistant. Coverage was 70% per round. MDA=mass drug administration. MORU=Mahidol Oxford Tropical Medicine Research Unit.

Discussion {#cesec50}
==========

Although individual models predicted different magnitudes of the effects of MDA, we found substantial consensus on which factors have the greatest influence on these effects, including both the characteristics of the programme and the setting in which MDA is applied. Percentage reductions were predicted to be highest in low-transmission settings and smaller populations, but were more transient in other settings, in line with evidence from field studies.[@bib2], [@bib3] Infection importation rates (when transmission is not very low) and the spacing between rounds (within the 4--6 week range examined) had little effect. The proportion of the population reached by at least one round of MDA per year and the duration of the programme had a large influence on effectiveness, and our analysis suggested that these factors should be the focus of operational efforts.

We did not formally analyse which differences between the models created the variation in predicted effects of MDA. MDA can substantially affect transmission in the short term, leading to different transmission dynamics from those analysed in in-depth comparisons of models of the effects of RTS,S.[@bib15] Differences between the models in basic epidemiological quantities, including duration of untreated infections and clinical immunity, could be relevant. Different levels of within-population heterogeneity in malaria exposure are assumed, which are crucial for the stability of transmission in low-prevalence settings. Seasonal variation makes transmission less stable at a given prevalence, whereas spatial heterogeneity can make transmission more stable. We did not include spatial heterogeneity in transmission levels, but it is likely to be crucial at very low transmission levels. Simulations of small subpopulations with 5--10% prevalence, diluted by other subpopulations of unexposed individuals, might be appropriate representations of large populations with 1% average prevalence. The size of such subpopulations and their degree of interconnection could then be crucial, because stochastic extinction is much more likely in smaller than in larger populations. Consideration of spatial structure in the models will be crucial for more realistic modelling of malaria elimination. In each model, the initial prevalence for simulations was fixed, but this value could correspond to very different epidemiological patterns, for example, of the immune status of human beings or vectorial capacity.

A key next step for the modelling groups is to continue using data from forthcoming trials of MDA to further validate the models and to continue efforts to understand how and why model predictions differ, such as under the HIV, tuberculosis, and neglected tropical diseases model consortiums.[@bib35], [@bib36] Use of modelling to understand the potential role of MDA in containing outbreaks after elimination, and to compare the predicted effects of MDA on drug resistance, will also be important.

The value of our simulations is that they show that, despite many differences in assumptions, there is a consensus between models on the relative influence of MDA operational characteristics. Many of our results accord with findings from MDA for lymphatic filariasis,[@bib37], [@bib38], [@bib39] although caution should be taken in extrapolating findings between the diseases in view of the generally much higher reproductive number and shorter generation time of malaria. Our results form one part of a broad evidence base, including growing evidence from malaria field trials, which should be considered when policy makers decide whether MDA is a useful strategy for their settings. This reassessment should balance the predicted benefits of MDA against equivalent investments in existing interventions, while considering other consequences such as the risk of spreading resistance. Under no circumstances did any of the models predict that MDA is an effective replacement for vector control, and indeed the overarching message from this model comparison is that, without some other sustained change, such as improved vector control, the effects of MDA are likely to be transient. When MDA is implemented, sustainability of the programme and maintenance of other interventions will be major challenges to ensure long-term reduction in malaria burden.
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[^1]: These authors contributed equally

[^2]: The standard intervention scenario was used as a basis for comparison and values were varied as shown. *Pf*PR~2--10~=*Plasmodium falciparum* parasite rate in children aged 2--10 years.

[^3]: Defined as the percentage of the population that takes the full course of drug that clears all parasites (the product of access to intervention, adherence, and drug efficacy). The denominator corresponds to the entire population; ineligible people (eg, pregnant women) and infants younger than 6 months are not included in mass drug administrations.

[^4]: The same people are treated in each round in the EMOD Disease Transmission Kernel, Imperial, and OpenMalaria models.

[^5]: Random individuals are treated in each round in the Mahidol Oxford Tropical Medicine Research Unit model.

[^6]: All the models are extensible to include other functionality (eg, different drugs, effects of drug resistance, effect on drug resistance, vector bionomics and details of vector control, different initial conditions, other concomitant interventions). A detailed comparison of EMOD DTK, Imperial, and OpenMalaria, including references to the data to which they are fitted, is available elsewhere.[@bib15] DTK=Disease Transmission Kernel. MORU=Mahidol Oxford Tropical Medicine Research Unit. MACEPA=Malaria Control and Elimination Partnership in Africa.
